Gilead Buys Ouro Medicines for $2.2 Billion

Gilead Sciences is acquiring Ouro Medicines in a deal valued at $2.2 billion, signaling a strategic move to bolster its oncology pipeline. The acquisition centers on Ouro's lead drug candidate, gamgertamig, which is designed to 'reset' the immune system to fight cancer. Gilead plans to advance this promising therapy, potentially through collaboration with other pharmaceutical partners, aiming to unlock significant future gains and address unmet needs in cancer treatment.